A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection
Authors
Yang, KejianWhalen, Barbara J.
Tirabassi, Rebecca S
Selin, Liisa K.
Levchenko, Tatyana S.
Torchilin, Vladimir P.
Kislauskis, Edward H.
Guberski, Dennis L.
UMass Chan Affiliations
Department of PathologyOral Vaccine Institute
Graduate School of Biomedical Sciences
Document Type
Journal ArticlePublication Date
2008-04-22Keywords
Administration, Intranasal; Animals; Animals, Newborn; Antibody Formation; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Humans; Immunity, Mucosal; *Immunization, Secondary; Liposomes; Mice; Mice, Inbred BALB C; Th1 Cells; Vaccines, DNA; Vaccinia virusLife Sciences
Medicine and Health Sciences
Metadata
Show full item recordAbstract
A variety of DNA vaccine prime and recombinant viral boost immunization strategies have been developed to enhance immune responses in humans, but inherent limitations to these strategies exist. There is still an overwhelming need to develop safe and effective approaches that raise broad humoral and T cell-mediated immune responses systemically and on mucosal surfaces. We have developed a novel mucosal immunization regimen that precludes the use of viral vectors yet induces potent T cell responses. Using hepatitis B surface Ag (HBsAg), we observed that vaccination of BALB/c mice with an i.m. HBsAg-DNA vaccine prime followed by an intranasal boost with HBsAg protein encapsulated in biologically inert liposomes enhanced humoral and T cell immune responses, particularly on mucosal surfaces. Intranasal live virus challenge with a recombinant vaccinia virus expressing HBsAg revealed a correlation between T cell immune responses and protection of immunized mice. A shortened immunization protocol was developed that was successful in both adult and neonatal mice. These results support the conclusion that this new approach is capable of generating a Th-type-1-biased, broad spectrum immune response, specifically at mucosal surfaces. The success of this design may provide a safe and effective vaccination alternative for human use.Source
J Immunol. 2008 May 1;180(9):6159-67.
DOI
10.4049/jimmunol.180.9.6159Permanent Link to this Item
http://hdl.handle.net/20.500.14038/32935PubMed ID
18424737Related Resources
ae974a485f413a2113503eed53cd6c53
10.4049/jimmunol.180.9.6159